here - Patent Docs
... Travenol Labs., 952 F.2d 388, 392 (Fed. Cir. 1991) (“Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention.”); In re Prindle, 297 F.2d 251, 254 (CCPA 1962). A person of ordinary skill in the art (“POSA”), however, would have been motivated to ...
... Travenol Labs., 952 F.2d 388, 392 (Fed. Cir. 1991) (“Mere recognition of latent properties in the prior art does not render nonobvious an otherwise known invention.”); In re Prindle, 297 F.2d 251, 254 (CCPA 1962). A person of ordinary skill in the art (“POSA”), however, would have been motivated to ...
Consensus Guidelines for the Management of
... approach are associated with a higher incidence of PONV when compared with general surgery as a reference group.20 The contribution of intraoperative opioids to PONV is weak, and there is no difference among the different opioids. A recent meta-analysis reaffirmed previously known PONV risk factors ...
... approach are associated with a higher incidence of PONV when compared with general surgery as a reference group.20 The contribution of intraoperative opioids to PONV is weak, and there is no difference among the different opioids. A recent meta-analysis reaffirmed previously known PONV risk factors ...
1. Exposure Data - IARC Monographs
... more neoplasms were found in the drug-treated patients because subsequent thyroidectomy was more frequent in this group (30% of drug-treated patients, as compared with 0.5% of those initially treated with 131I and 1.2% of those treated with primary thyroidectomy), which provided more opportunity for ...
... more neoplasms were found in the drug-treated patients because subsequent thyroidectomy was more frequent in this group (30% of drug-treated patients, as compared with 0.5% of those initially treated with 131I and 1.2% of those treated with primary thyroidectomy), which provided more opportunity for ...
Riboflavin 0.1% (VibeX) for the treatment of keratoconus
... reepithelialization was complete after 3 days of soft contact lens bandage and subjectively patients reported a very small degree of discomfort. In conclusion the Avedro, Inc.’s standard riboflavin solution complies well with other solutions currently available on the market for epithelium-off cross ...
... reepithelialization was complete after 3 days of soft contact lens bandage and subjectively patients reported a very small degree of discomfort. In conclusion the Avedro, Inc.’s standard riboflavin solution complies well with other solutions currently available on the market for epithelium-off cross ...
DOI: 10.1161/CIRCULATIONAHA.109.919456 published online Mar
... Background—The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown. Methods and Results—Patients with stable coronary artery disease on aspirin therapy received a 300-m ...
... Background—The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown. Methods and Results—Patients with stable coronary artery disease on aspirin therapy received a 300-m ...
Comparative study of the anesthetic efficacy of 4
... Study design: A randomized double-blind clinical trial was conducted of 30 patients programmed for the bilateral surgical extraction of symmetrical lower third molars in the context of the Master of Oral Surgery and Implantology (University of Barcelona, Barcelona, Spain). Following the obtainment o ...
... Study design: A randomized double-blind clinical trial was conducted of 30 patients programmed for the bilateral surgical extraction of symmetrical lower third molars in the context of the Master of Oral Surgery and Implantology (University of Barcelona, Barcelona, Spain). Following the obtainment o ...
Polyethylene Glycol 3350 (PEG 3350) Frequently Asked
... Generally speaking, if your child has been prescribed PEG 3350 as part of his/her treatment plan, and you feel this medicine provides benefit, you should feel safe continuing PEG 3350. At this time, PEG 3350 appears to be safe based on current medical literature. We recommend discussing any concerns ...
... Generally speaking, if your child has been prescribed PEG 3350 as part of his/her treatment plan, and you feel this medicine provides benefit, you should feel safe continuing PEG 3350. At this time, PEG 3350 appears to be safe based on current medical literature. We recommend discussing any concerns ...
Drug formulary - Johns Hopkins University
... ketamine hydrochloride is approved for use in cats and nonhuman primates, and the package insert provides extensive dosage information. Ketamine is not approved for use in any other species--and in fact by itself, does not work well in other species. In combination, however, with other tranquilizers ...
... ketamine hydrochloride is approved for use in cats and nonhuman primates, and the package insert provides extensive dosage information. Ketamine is not approved for use in any other species--and in fact by itself, does not work well in other species. In combination, however, with other tranquilizers ...
Carbamazepine ER Capsules, 300 mg 120 count
... HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN (see WARNINGS and PRECAUTIONS/Laboratory Tests). ...
... HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN (see WARNINGS and PRECAUTIONS/Laboratory Tests). ...
EC-NAPROSYN (naproxen delayed-release tablets) NAPROSYN (naproxen tablets)
... these adverse events were gastrointestinal events. In clinical studies in patients with rheumatoid arthritis, osteoarthritis, and juvenile arthritis, naproxen has been shown to be comparable to aspirin and indomethacin in controlling the aforementioned measures of disease activity, but the frequency ...
... these adverse events were gastrointestinal events. In clinical studies in patients with rheumatoid arthritis, osteoarthritis, and juvenile arthritis, naproxen has been shown to be comparable to aspirin and indomethacin in controlling the aforementioned measures of disease activity, but the frequency ...
Methadone-Drug Interactions
... generally remained within acceptable limits (Maremmani et al. 2005; Martell et al. 2005). Often, these heart rhythm changes were in patients taking medications or drugs in addition to methadone, or having cardiac risk factors that might normally be of concern (Leavitt and Krantz 2003). In the larges ...
... generally remained within acceptable limits (Maremmani et al. 2005; Martell et al. 2005). Often, these heart rhythm changes were in patients taking medications or drugs in addition to methadone, or having cardiac risk factors that might normally be of concern (Leavitt and Krantz 2003). In the larges ...
History of Medicinal Cannabis
... my immediate attendance at the Hospital, as the patient's symptoms were very peculiar and formidable. I went to the Hospital without delay, and found him lying on his cot quite insensible, but breathing with perfect regularity, his pulse and skin natural, and the pupils freely contractile on the app ...
... my immediate attendance at the Hospital, as the patient's symptoms were very peculiar and formidable. I went to the Hospital without delay, and found him lying on his cot quite insensible, but breathing with perfect regularity, his pulse and skin natural, and the pupils freely contractile on the app ...
Anaesthesia - University Hospitals Bristol NHS Foundation Trust
... offer literature searching services as well as training and guidance in searching the evidence and critical appraisal – just email me at [email protected] Outreach: Your Outreach Librarian can help facilitate evidence-based practise for all in the oral and maxillofacial surgery team, as well ...
... offer literature searching services as well as training and guidance in searching the evidence and critical appraisal – just email me at [email protected] Outreach: Your Outreach Librarian can help facilitate evidence-based practise for all in the oral and maxillofacial surgery team, as well ...
Evaluation of Pharmacokinetic Interaction between PA
... PA-824 was highly active as monotherapy in a 14-day dose ranging early bactericidal activity (EBA) study in humans where similar efficacy profiles were observed across all doses assessed (200 to 1,200 mg/day) (5). In EBA studies, the rate of change over time in the number of M. tuberculosis CFU per ...
... PA-824 was highly active as monotherapy in a 14-day dose ranging early bactericidal activity (EBA) study in humans where similar efficacy profiles were observed across all doses assessed (200 to 1,200 mg/day) (5). In EBA studies, the rate of change over time in the number of M. tuberculosis CFU per ...
Does Oral Trenbolone Really Have the Best Steroid
... and SERMs are supposed to prevent their effects. However, with oral Trenbolone, users are split as to whether a SERM should be a part of PCT with this steroid. Trenbolone binds to progesterone receptors and some assume a SERM would not have any effect on the progesterone receptors. Some are determin ...
... and SERMs are supposed to prevent their effects. However, with oral Trenbolone, users are split as to whether a SERM should be a part of PCT with this steroid. Trenbolone binds to progesterone receptors and some assume a SERM would not have any effect on the progesterone receptors. Some are determin ...
AusPAR: Trastuzumab emtansine - Therapeutic Goods Administration
... The company has proposed a shelf life of 3 years when stored at 2-8°C based on real time storage of a single Phase III batch and stressed storage. The evaluator recommends a shelf life of 24 months at 2-8°C be applied equally to the 100 mg and 160 mg Drug Product presentations based on real time sto ...
... The company has proposed a shelf life of 3 years when stored at 2-8°C based on real time storage of a single Phase III batch and stressed storage. The evaluator recommends a shelf life of 24 months at 2-8°C be applied equally to the 100 mg and 160 mg Drug Product presentations based on real time sto ...
Ceftin (cefuroxime axetil) tablets USP - GlaxoSmithKline
... compared with that of the fasting state and tend to cancel the effect of enhanced postprandial absorption. In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral contraceptives. Drug-Laboratory Test I ...
... compared with that of the fasting state and tend to cancel the effect of enhanced postprandial absorption. In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral contraceptives. Drug-Laboratory Test I ...
Effect of Glyburide–Metformin Combination Tablet in Patients with
... Hsin-Hsi Chien1, Chwen-Tzuei Chang2, Nain-Feng Chu3, Sheng-Hwu Hsieh4, Yu-Yao Huang5, ...
... Hsin-Hsi Chien1, Chwen-Tzuei Chang2, Nain-Feng Chu3, Sheng-Hwu Hsieh4, Yu-Yao Huang5, ...
Modification of Microbial Polyacids for Drug Delivery Systems U
... Polymers are becoming preferred materials in biomedical applications because of their vast diversity of properties, functionalities and applications. Properties ...
... Polymers are becoming preferred materials in biomedical applications because of their vast diversity of properties, functionalities and applications. Properties ...
Spreading of Semisolid Formulations: An Update
... final behavior, including their spreading qualities on the substrate. Spreadability can be measured with various types of viscometers and varies according to the formulator’s requirement. In suspension ointments, a logarithmic regression with a negative correlation was found between viscosity and de ...
... final behavior, including their spreading qualities on the substrate. Spreadability can be measured with various types of viscometers and varies according to the formulator’s requirement. In suspension ointments, a logarithmic regression with a negative correlation was found between viscosity and de ...
drug registration guidance document
... Permohonan Pendaftaran Keluaran Ubat Tradisional” Second Edition, December 1998. The contents of this version include: ...
... Permohonan Pendaftaran Keluaran Ubat Tradisional” Second Edition, December 1998. The contents of this version include: ...
Bad Pharma
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.